ライフサイエンスコーパス: propranolol

1 rred after local beta-adrenoceptor blockade (propranolol).

2 ta-AR antagonists (1 muM prazosin and 10 muM propranolol).

3 renergic receptor blockade (phentolamine and propranolol).

4 ide, and warfarin) and bases (metoprolol and propranolol).

5 ndirectly alter contractility (verapamil and propranolol).

6 fect was blocked with intra-BLA infusions of propranolol.

7 1 wk of oral treatment with the beta-blocker propranolol.

8 the full SERS spectral data and the level of propranolol.

9 space could be correlated with the level of propranolol.

10 action tremor, which is usually treated with propranolol.

11 ther resection of the carotid sinus nerve or propranolol.

12 and in vitro ADME-tox profiles comparable to propranolol.

13 n the placebo group and the groups receiving propranolol.

14 ) included patients initiating bisoprolol or propranolol.

15 (ISO), or the beta-adrenoceptor antagonist, propranolol.

16 ation was not blocked with betaAR antagonist propranolol.

17 Both are prevented by treatment with propranolol.

18 72 months) underwent treatment with systemic propranolol.

19 n deficits, and this is blocked by intra-BLA propranolol.

20 o better than aspirin, dihydroergotamine, or propranolol.

21 peridin-1-yl)propan-2-ol (A-core)] recalling propranolol.

22 olff-Parkinson-White, comparing digoxin with propranolol.

23 r injection; P<0.0001) and were inhibited by propranolol.

24 rence in infants treated with digoxin versus propranolol.

25 c prophylaxis of SVT in infants: digoxin and propranolol.

26 was prevented by systemic administration of propranolol.

27 ts metabolic stability was much greater than propranolol.

28 er(24) unless the mice were pre-treated with propranolol.

29 he study, 27 randomized to digoxin and 34 to propranolol.

30 TSD, but not necessarily in combination with propranolol.

31 o have poorer outcomes than those not taking propranolol.

32 All effects on the CR were wholly blocked by propranolol.

33 s effect when administered concurrently with propranolol.

34 d DR, and DH Fos was decreased by systemic S-propranolol.

35 tation since these effects were abolished by propranolol.

36 propranolol-d7 and varied concentrations of propranolol.

37 sated cirrhosis before and after intravenous propranolol (0.15 mg/kg): 194 patients had an HVPG >/=10

38 injection of vehicle, mifepristone 30 mg/kg, propranolol 10 mg/kg, or both.

39 were mitigated by systemic administration of propranolol (10 mg/kg, i.p.), a beta-noradrenergic recep

40 lol era [pre-propranolol 25/48 (52%) vs post-propranolol 16/76 (21%) (P = 0.0003)].

41 I, Naples, Italy, were treated with systemic propranolol (2 mg/kg body weight per day).

42 1), the beta-adrenergic receptor antagonist propranolol (2 mug) or vehicle (Experiment 2), or the be

43 The second patient was taking amiodarone and propranolol; 2 hrs after receiving sofosbuvir and daclat

44 creased markedly in the propranolol era [pre-propranolol 25/48 (52%) vs post-propranolol 16/76 (21%)

45 To evaluate the efficacy of propranolol (3 mg/kg/day) in the treatment of periocular

46 A single oral dose of propranolol (40 mg) significantly increased beta band (1

47 s of the beta-adrenergic receptor antagonist propranolol (40 mg) using a between-subjects, double-bli

48 o or the noradrenergic beta-receptor blocker propranolol (40 mg).

49 Osmotic mini pumps containing either propranolol (5 mg/kg/d) or vehicle alone were implanted

50 nergic and 5-HT1A/1B receptor antagonist), R-propranolol (5-HT1A/1B receptor antagonist), or racemic

51 sm of COMT, and randomly allocated to either propranolol 60 mg twice daily or placebo.

52 microglia and macrophages were prevented by propranolol, a beta-adrenergic receptor antagonist.

53 increased in sensory denervation models, and propranolol, a beta2-adrenergic antagonist, rescues bone

54 erapeutic relevance, the authors showed that propranolol, a commonly prescribed beta-blocker, can red

55 Propranolol, a generic beta-adrenergic antagonist, decre

56 Propranolol, a non-selective beta-blocker, has been foun

57 Propranolol, a nonselective beta-adrenergic receptor blo

58 n of the BLA by the noradrenergic antagonist propranolol abolished the effect of GR agonist administr

59 The beta-adrenergic receptor antagonist propranolol, administered in conjunction with memory rea

60 RANKL expression by MSCs decreased after propranolol administration and increased after isoproter

61 Moreover, propranolol administration dampened the stress-induced i

62 Whether propranolol administration for 1 year after injury provi

63 n contrast, neither intra-BLA nor intra-mPFC propranolol affected delayed extinction learning.

64 -118 551 (beta1 and beta2 antagonists), or S-propranolol alone.

65 ne, terbutaline, metaproterenol, salmeterol, propranolol, alprenolol, bisoprolol, ICI 118,551, and bu

66 BLA inactivation by propranolol also blocked the effect of GR agonist admini

67 Propranolol also suppressed PARP1 activation in peripher

68 onic use of the beta-adrenoceptor antagonist propranolol and an increased risk of Parkinson's disease

69 nergic-induced arrhythmias by beta-blockers (propranolol and carvedilol), flecainide, and the neurona

70 control mice (in the presence or absence of propranolol and isoproterenol) and defined pathways that

71 0), or medical reduction of portal pressure (propranolol and isosorbide-5-mononitrate; n = 95).

72 face sampling exemplified by the analysis of propranolol and its hydroxypropranolol glucuronide phase

73 tem were established using the drug molecule propranolol and its isotope labeled internal standard in

74 Propranolol and metoprolol (highly permeable compounds)

75 Propranolol and metoprolol showed a rapid absorption and

76 This could be attenuated by systemic propranolol and mimicked by chemogenetic activation of t

77 Propranolol and nadolol are equally effective, whereas s

78 -adrenergic receptor blockers (specifically, propranolol and nadolol) and sodium and transient outwar

79 However, after treatment with propranolol and PKA, the R21C cTnI mutation reduced (R21

80 ality or psychophysiological measures in the propranolol and placebo groups.

81 Instead, we suggest that propranolol and salbutamol may affect both tremor and co

82 s, the sympathetic nervous system (SNS) with propranolol and the hypothalamic-pituitary-adrenal axis

83 g nonselective beta-blockers, including oral propranolol and topical timolol.

84 g contaminants (caffeine, ciprofloxacin, and propranolol) and two model compounds (fluorescein and su

85 idine), beta-adrenergic receptor antagonist (propranolol), and beta(1)- and beta(2)-antagonist (betax

86 ency (HF) fraction of HRV in the presence of propranolol, and a decrease in expression of the G-prote

87 in vivo can be blocked with the beta-blocker propranolol, and by knockdown of RANK expression in MDA-

88 acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazepine (>80%) was achieved withi

89 Transformation of trimethoprim, propranolol, and carbamazepine was attributed to direct

90 60%, five (atenolol, metoprolol, celiprolol, propranolol, and flecainide) displayed EFr.

91 rst cardiac events for atenolol, metoprolol, propranolol, and nadolol were 0.71 (0.50 to 1.01), 0.70

92 gen species also reacted with emtricitabine, propranolol, and other trace organic contaminants common

93 hotolysis rates for atenolol, carbamazepine, propranolol, and sulfamethoxazole in wetland water under

94 milar to the effect of the betaAR antagonist propranolol, and this effect was reversed by the mGlu3-n

95 a limit of detection of 2.36 ng/mL (7.97 nM) propranolol, and this is significantly lower (>25 times)

96 etermined limits of detection for serotonin, propranolol, and tryptophan were 51, 37, and 280 nM, res

97 included clonidine, flunarizine, pizotifen, propranolol, and valproate.

98 rozil, ibuprofen, ketoprofen, norethindrone, propranolol, and warfarin) with differing modes of actio

99 Both riluzole and propranolol are efficient sodium channel blockers.

100 The current treatments, corticosteroid or propranolol, are administered for several months and can

101 rational redesign of a given pharmaceutical (Propranolol as an example).

102 S, we chose the beta-adrenergic blocker drug propranolol as the target analyte.

103 Propranolol at 3 mg/kg/day was clinically and radiologic

104 corresponding to the decrease in transfer of propranolol at an aqueous-1,2-dichloroethane interface.

105 e combined administration of oxandrolone and propranolol at the same doses, for 1 year after burn.

106 TAC mice treated with propranolol attenuated the rate of (18)F-FDG uptake, dim

107 Combined administration of oxandrolone and propranolol attenuates burn-induced growth arrest in ped

108 ss and noise slowed down reaction times, but propranolol augmented the interaction between these main

109 e of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for

110 traditional beta-blockers (eg, atenolol and propranolol), because there are currently no mortality a

111 tion of the beta-adrenoreceptor (AR) blocker propranolol before femur osteotomy prevented bone marrow

112 n of the beta-adrenergic receptor antagonist propranolol before memory retrieval, but not after (duri

113 seeking behavior on ED1 following 10 mg/kg S-propranolol (beta-adrenergic and 5-HT1A/1B receptor anta

114 Propranolol (beta-adrenergic receptor (beta-Ad) antagoni

115 were treated in counter-balanced order with propranolol (beta-AR antagonist), terazosin (alpha1-AR a

116 ules (R)-Naftopidil (alpha1-blocker) and (S)-Propranolol (beta-blocker) as a key step via AKR of sing

117 The beta-receptor antagonist propranolol blocked the inhibitory effect of (R)-albuter

118 drenoceptor activity with local infusions of propranolol blocked the memory retrieval impairment indu

119 a memory selectivity bias was insensitive to propranolol but sensitive to amisulpride, consistent wit

120 ioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is rec

121 mon treatment regimen was 2 mg/kg daily oral propranolol, but intralesional and topical beta-blockers

122 tting, we demonstrated that isoproterenol, S-propranolol, CGP-12177 [4-[3-[(1,1-dimethylethyl)amino]2

123 in asthma, showing no significant effect of propranolol compared with placebo on either methacholine

124 Average propranolol concentrations determined with the laser "cu

125 ensitive to amisulpride but was sensitive to propranolol, consistent with a dominant noradrenaline ef

126 s containing the same fixed concentration of propranolol-d7 and varied concentrations of propranolol.

127 nt, which contained a known concentration of propranolol-d7 as an internal standard.

128 of the beta1-, beta2-adrenoceptor antagonist propranolol decreases cardiac work and resting energy ex

129 ruption of reconsolidation by post-retrieval propranolol degrades the emotional/motivational impact o

130 bited a 6.5-times higher current density for propranolol detection due to the enhanced ion flux arisi

131 d ternary equi-effective mixture exposure to propranolol, diazepam, and carbamazepine on the crustace

132 Propranolol during reactivation specifically reduced the

133 structures were active (but not modulated by propranolol) during memory reactivation.

134 /kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggesting a need for new

135 /kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggesting a need for new

136 the molecular mechanism identified the R(+)-propranolol enantiomer as a small molecule inhibitor of

137 The bound concentration of propranolol enantiomers in the presence of AGP was found

138 ransfer potential of the uncomplexed form of propranolol enantiomers.

139 Propranolol enhanced cocaine reinforcement and reduced p

140 requiring surgery decreased markedly in the propranolol era [pre-propranolol 25/48 (52%) vs post-pro

141 Collectively, these data suggest that propranolol exerts its suppressive effects on hemangioma

142 e data on toxicological transcriptomics from propranolol exposure, and with microRNA data from IHs an

143 xposure, and with microRNA data from IHs and propranolol exposure.

144 Four months of treatment with oral propranolol for eyelid infantile capillary hemangiomas l

145 d to be greater for (S)-propranolol than (R)-propranolol for solutions containing constant concentrat

146 were treated with varying concentrations of propranolol for up to 4 days.

147 Propranolol given for 1 month postburn blunts this respo

148 owever, in the placebo group, but not in the propranolol group, memory vividness significantly decrea

149 Propranolol has a significantly better QTc shortening ef

150 e combined administration of oxandrolone and propranolol has added benefit.

151 The nonselective beta-blocker propranolol has become first-line therapy for the treatm

152 Propranolol has been found to be effective in treatment

153 Oral propranolol has been used to treat complicated infantile

154 Thus, propranolol has diverse effects on KSHV-infected cells,

155 First-line pharmacotherapy with propranolol has reduced but not abolished the need for s

156 Sugar starter cores were layered with propranolol HCl and subsequently coated with Kollicoat S

157 Propranolol HCl, as well as very small sugar particles f

158 that blocking beta-adrenergic signaling with propranolol hydrochloride disrupts angiosarcoma cell sur

159 l hydrochloride, the binding of (S)- and (R)-propranolol hydrochloride to the protein results in a de

160 A combination of propranolol hydrochloride, 40 mg 3 times a day, paclitax

161 The patient was immediately administered propranolol hydrochloride, 40 mg twice a day, as his wor

162 ted with daily intraperitoneal injections of propranolol hydrochloride.

163 Known adverse events associated with propranolol (hypoglycemia, hypotension, bradycardia, and

164 before and after systemic beta-blockade with propranolol in 17 young men, 17 young women and 15 postm

165 ccessful treatment of pericardial edema with propranolol in a patient with Hypotrichosis-Lymphedema-T

166 ly relevant concentrations of metoprolol and propranolol in blood samples were measured over several

167 (5-HT1A/1B receptor antagonist), or racemic propranolol in both male and female rats.

168 stem for online and absolute quantitation of propranolol in mouse brain, kidney, and liver thin tissu

169 omized placebo-controlled crossover trial of propranolol in patients with mild-to-moderate asthma rec

170 s in transduction during beta-blockade using propranolol in YW, YM and PMW.

171 Blocking noradrenaline function (40 mg propranolol), in contrast, abolishes an arousal-related

172 Additionally, propranolol induced lytic gene expression in association

173 2alpha) instead of HIF-1alpha, and also that propranolol-induced apoptosis in endothelial cells may o

174 We used bilateral intracranial infusions of propranolol into either the infralimbic division of the

175 Propranolol is a nonselective beta-adrenergic receptor a

176 Propranolol is an approved non-selective beta-adrenergic

177 Propranolol is an approved treatment for IHs, but its me

178 Oral propranolol is now the first-line treatment, which shoul

179 high risk for subsequent cardiac events, and propranolol is the least effective drug in this high-ris

180 Treatment with propranolol led to a dose dependent cytotoxic effect in

181 Propranolol may be a helpful adjunct to behavioral thera

182 Propranolol may be a useful adjunct to behavioral therap

183 Recent evidence has suggested that propranolol may be effective in patients suffering from

184 with small molecular changes as compared to propranolol molecule were generated by a nontargeted pho

185 of the tumor before and after only 1 week of propranolol monotherapy revealed a reduction in the prol

186 ver, given the very low risk associated with propranolol, most clinicians are unlikely to change thei

187 eters of 382 LQT1/LQT2 patients initiated on propranolol (n = 134), metoprolol (n = 147), and nadolol

188 e of 40 mg of the noradrenergic beta-blocker propranolol (n = 15), double-blind and placebo-controlle

189 randomized to control (n = 89) or 4 mg/kg/d propranolol (n = 90) for 12 months postburn.

190 d before and at 1-3 months of treatment with propranolol/nadolol plus endoscopic band ligation.

191 =12 mm Hg) indicates a good prognosis during propranolol/nadolol treatment but requires two HVPG meas

192 ic patients receiving metoprolol compared to propranolol/nadolol.

193 ng the effects of the beta-adrenergic agents propranolol (non-selective beta-antagonist) and salbutam

194 The effect of the noradrenergic inhibitor propranolol on (14)C-FBnTP response to cold stimulation

195 The opposite direction of the effects of propranolol on corticomuscular coherence and tremor, and

196 s provide a plausible mechanism of action of propranolol on regression of infantile hemangiomas.

197 etreatment with 1 mg (100 g body weight)(-1) propranolol or 6 mg (100 g body weight)(-1) iopanoic aci

198 ered the beta-adrenergic receptor antagonist propranolol or a placebo before they reactivated previou

199 by either beta-adrenoreceptor blockade with propranolol or adrenalectomy.

200 beta-Adrenoceptor blockade with propranolol or inhibition of its downstream cAMP/PKA sig

201 e then intraperitoneally injected by saline, propranolol or isoproterenol.

202 ective actually are beta3-sparing, including propranolol or nadolol.

203 The beta-receptor blocker propranolol or PKA inhibitor Rp-cAMPS blocks the effects

204 s underwent a 6- to 8-week dose titration of propranolol or placebo as tolerated to a maximum of 80 m

205 macological blockade of either sympathetic - propranolol - or parasympathetic - methylatropine - sign

206 beta-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade plus cholinergic

207 common beta-blockers (atenolol, metoprolol, propranolol, or nadolol).

208 infants with periocular IH were treated with propranolol (oral) for 2-12 months (mean: 7.1 months).

209 f patients on digoxin and 31% of patients on propranolol (P=0.25).

210 patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrence

211 s of trial treatment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was select

212 nucleotides (ATP and CTP), N-ethylmaleimide, propranolol, phenylglyoxal, and divalent cations (Ca(2+)

213 pling to study the permeation of a weak base propranolol (PPL), and evaluate the impact of including

214 lethal arrhythmias were rescued, in part, by propranolol pre-treatment.

215 Concurrent administration of propranolol prevents this effect.

216 rescued the IED; animals receiving intra-BLA propranolol prior to immediate extinction showed less sp

217 s after intravenous administration of either propranolol (PROP), or glycopyrrolate (GLYC), or PROP an

218 clotrimazole (CTZ), clofibric acid (CFA) and propranolol (PRP), found responses to IBU and CFA, but n

219 ng was subsequently used to provide accurate propranolol quantification within all biofluids with hig

220 fluids spiked with varying concentrations of propranolol ranging from 0 to 120 muM, and clear trends

221 ple, systemic or intra-BLA administration of propranolol reduces the immediate extinction deficit (IE

222 of 88% of patients who received the selected propranolol regimen showed improvement by week 5, versus

223 y assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per

224 ole in vascular neoplasms, and suggests R(+)-propranolol repurposing to numerous indications ranging

225 nterestingly, intra-BLA, but not intra-mPFC, propranolol rescued the IED; animals receiving intra-BLA

226 hat systemic beta-adrenoceptor blockade with propranolol rescues the IED, but impairs delayed extinct

227 9.9-fold for 1 microM CGP 12177 and 1 microM propranolol, respectively) and abolished in beta1-adreno

228 presence of 1 microM CGP 12177 and 1 microM propranolol, respectively.

229 intra-arterial infusions of phentolamine and propranolol, respectively.

230 f 2.7 and 1.3 x 10(5) M(-1) for (S)- and (R)-propranolol, respectively.

231 ly transcribed upon exposure to diazepam and propranolol, respectively.

232 the beta-noradrenergic receptor antagonist, propranolol, reversed the decrease, suggesting that the

233 erved antagonistic effect of the A allele on propranolol's efficacy was opposite the synergistic effe

234 ll as a small set of putative biomarkers for propranolol's mechanism of action for IHs, namely EPAS1,

235 rt that the post-retrieval administration of propranolol selectively attenuates a sign-tracking CR, a

236 Combined use of oxandrolone and propranolol shortened the period of growth arrest by 84

237 removed from water, while the organic cation propranolol showed biouptake similar to that of TCC.

238 Propranolol significantly diminished the effect of cold

239 In contrast, the antagonist propranolol significantly increased maternal aggression

240 revealed that noradrenergic blockade (40 mg propranolol) significantly increased metacognitive perfo

241 The drugs are propranolol, simvastatin, norfloxacin, and warfarin, whi

242 cacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age wit

243 ction and quantification of the beta-blocker propranolol spiked into human serum, plasma, and urine a

244 In this hypermetabolic, hypoglycaemic state, propranolol stimulated a rise in P aC O2, suggestive of

245 beta-antagonist (propranolol) suppressed subchondral bone loss and osteoc

246 sence of AGP was found to be greater for (S)-propranolol than (R)-propranolol for solutions containin

247 After propranolol, the HVPG decreased significantly in both gr

248 tenuated by the beta-adrenoceptor antagonist propranolol, the mixed alpha-/beta-adrenoceptor antagoni

249 Propranolol therapy (from 2008) was sufficient for sympt

250 Despite the clinical benefit of propranolol therapy in hemangioma, the mechanistic under

251 These data bring into question whether propranolol through inhibition of beta-adrenergic recept

252 Control animals treated with intravenous propranolol to block sympathetically mediated chronotrop

253 disturbances resulting from systemic use of propranolol to treat infantile hemangioma.

254 Propranolol-treated mice demonstrated a 50% reduction in

255 ing RNA isolated from retinas of control and propranolol-treated pups.

256 After propranolol treatment (-PKA), the pCa-tension relationsh

257 Propranolol treatment also did not change retinal expres

258 Propranolol treatment decreased serum FGF23 and loss of

259 Propranolol treatment for 12 months after thermal injury

260 e of incomplete development, the efficacy of propranolol treatment in retinopathy needs to be evaluat

261 cal trials are currently ongoing to evaluate propranolol treatment in stage 2 ROP patients who tend t

262 ions and pathways that were normalized after propranolol treatment in the mdx model.

263 We used propranolol treatment of mice to reduce the level of tro

264 less future recovery of responding, whereas propranolol treatment reduced the benefit seen with comp

265 se pre-clinical model of HLTRS, we show that propranolol treatment rescues its corneal neo-vascularis

266 d norepinephrine levels in the pancreas, and propranolol treatment reversed glucose intolerance in th

267 Long-term propranolol treatment significantly reduced the percenta

268 Propranolol treatment via three routes and up to 30 time

269 Three routes of propranolol treatment were assessed from P12 to P16: ora

270 rrhythmias were significantly decreased with propranolol treatment.

271 e of the treatment approaches at any dose of propranolol (up to 60 mg/kg/day) were effective in preve

272 one case in 10 000 patients after 5 years of propranolol use, and would be considered a very rare adv

273 Experiments with propranolol used a double-blind, placebo-controlled cros

274 re very few adverse effects from the dose of propranolol used.

275 ine or histamine challenge after exposure to propranolol versus placebo.

276 tamine challenge was partially attenuated by propranolol versus placebo: FEV1% mean difference, 5.28

277 ea under the naphthalene ring vibration from propranolol was 133.1 ng/mL (0.45 muM), 156.8 ng/mL (0.5

278 Propranolol was compared with valproate as well as behav

279 This trial showed that propranolol was effective at a dose of 3 mg per kilogram

280 ric detection of the protonated beta-blocker propranolol was explored at arrays of nanoscale interfac

281 In contrast, S-propranolol was most effective in females in reducing dr

282 The QTc shortening with propranolol was significantly greater than with other be

283 Propranolol was stopped in 1 case for hypotension and in

284 al of 10% of patients in whom treatment with propranolol was successful required systemic retreatment

285 aximum length of treatment was 4 months, and propranolol was suspended when complete regression of le

286 ent events differed by drug (p = 0.004), and propranolol was the least effective compared with the ot

287 mination of the enantiomers of a basic drug, propranolol, was achieved at a micro liquid-liquid inter

288 (400 mg amisulpride) or noradrenaline (40 mg propranolol) we examined their specific contribution to

289 and trimethoprim, while sulfamethoxazole and propranolol were attenuated mainly via photolysis.

290 Patients with refractory ascites taking propranolol were found to have poorer outcomes than thos

291 udy, patients with refractory ascites taking propranolol were found to have poorer outcomes, perhaps

292 During summer, atenolol, metoprolol, and propranolol were rapidly attenuated in the pilot-scale s

293 Amiodarone and propranolol were stopped, but the patient continued rece

294 Two benzazaborinine analogues of propranolol were synthesized and extensively profiled in

295 formation rates increased for metoprolol and propranolol when algal photosynthesis was supported by i

296 l tumors may confer similar efficacy as oral propranolol while reducing systemic effects.

297 n through co-treatment with the beta-blocker propranolol, while leaving the peripheral effect intact,

298 nts (n = 15) received a single dose of 40 mg propranolol without memory reactivation.

299 Memory reactivation alone or propranolol without reactivation had no effect on subseq

300 Propranolol worsened AILI.